Extended Data Fig. 5: GP73 stimulates gluconeogenesis.
From: GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia
a, Glucose production in PMHs treated with 32 nM rmGP73 for the indicated times. P = 0.0159 for rmGP73 versus PBS (4 h), P = 0.0050 for rmGP73 versus PBS (8 h), P < 0.0001 for rmGP73 versus PBS (1 h and 2 h) by two-tailed Student’s t-tests. b, Glucose production in primary rat hepatocytes treated with the indicated concentrations of rrGP73 for 2 h. P < 0.0001 for 4 nM versus 0 nM, 8 nM versus 0 nM, 16 nM versus 0 nM, 32 nM versus 0 nM and 64 nM versus 0 nM by one-way ANOVA followed by Bonferroni’s post hoc test. c, Glucose production in PMHs treated with 32 nM rmGP73 with or without anti-GP73 antibody for 2 h. P = 0.0001 for rmGP73 versus PBS (isotype), P < 0.0001 for anti-GP73 versus isotype (rmGP73) by one-way ANOVA followed by Bonferroni’s post hoc test. d-e, Intracellular cAMP levels (d) or hepatocyte PKA activity (e) in PMHs treated with 32 nM rmGP73 for 2 h. P = 0.0031 for rmGP73 versus PBS (d) and P < 0.0001 for rmGP73 versus PBS (e) by two-tailed Student’s t-tests. Cell-based studies were performed independently at least three times with comparable results. The data were the means ± SEMs. *P < 0.05; **P < 0.01; ***P < 0.001.
